Ureaplasma urealyticum DNA (U. urealyticum DNA)

Ureaplasma urealyticum DNA represents the genetic material of a small, cell-wall-deficient bacterium that commonly inhabits the human urogenital tract. As a therapeutic target, the DNA itself is not typically the direct binding site for drugs; rather, the enzymes responsible for its replication and maintenance, such as DNA gyrase and Topoisomerase IV, are the primary targets for fluoroquinolone antibiotics (StatPearls, 2023). These drugs interfere with the breaking and rejoining of DNA strands, leading to double-stranded DNA breaks and bacterial cell death (PubMed, PMID: 24595040). U. urealyticum is associated with various clinical conditions, including non-gonococcal urethritis, pregnancy complications, and neonatal infections (NIH, 2022). While DNA-based diagnostics like PCR are the gold standard for identifying the pathogen, therapeutic strategies focus on inhibiting the machinery that processes this DNA to halt bacterial proliferation.

Other names

Ureaplasma urealyticum genomeUreaplasma urealyticum deoxyribonucleic acid

Inhibition of DNA replication and transcription by targeting DNA gyrase and Topoisomerase IV enzymes, which manage DNA supercoiling and separation.